Flurbiprofen (dl-Flurbiprofen) 是一种高效的，具有口服活性的非甾体抗炎化合物，有退热止痛活性, 常用于炎症性疾病 (包括骨关节炎、类风湿关节炎) 的研究。Flurbiprofen 是一种非选择性的环氧合酶 (COX) 抑制剂，可用于结肠癌的研究。
| 生物活性 | Flurbiprofen (dl-Flurbiprofen) is a potent, orally active nonsteroidal anti-inflammatory agent (NSAIA/NSAID), with antipyretic and analgesic activities. Flurbiprofen is commonly used for the research of inflammatory diseases, including osteoarthritis and rheumatoid arthritis. Flurbiprofen is a non-selectivecyclooxygenase (COX)inhibitor that can be used for the research of colorectalcancer[1][2][3]. |
| IC50& Target[1] | |
体外研究
(In Vitro) | Flurbiprofen (2-20 nM; 12-48 hours) significantly decreases SW620 cells proliferation in a concentration- and time-dependent manner[1].
Flurbiprofen (10 nM; 24 hours) decreases COX-2 expression[1].
Flurbiprofen (10 nM; 24 hours) inhibits the expression of inflammatory factors by inhibiting COX-2[1].
Flurbiprofen (10 nM; 24 hours) promotes the apoptosis of colorectal cancer cells by inhibiting COX-2[1].
Cell Proliferation Assay[1] | Cell Line: | SW620 cells | | Concentration: | 2 nM, 4 nM, 10 nM, 20 nM | | Incubation Time: | 12 hours, 24 hours, 48 hours | | Result: | Inhibited colorectal cancer cell proliferation. |
Western Blot Analysis[1] | Cell Line: | SW620 cells | | Concentration: | 10 nM | | Incubation Time: | 24 hours | | Result: | Significantly decreased the protein and mRNA levels of COX-2. |
RT-PCR[1] | Cell Line: | SW620 cells | | Concentration: | 10 nM | | Incubation Time: | 24 hours | | Result: | Decreased COX-2 mRNA expression levels |
Apoptosis Analysis[1] | Cell Line: | SW620 cells | | Concentration: | 10 nM | | Incubation Time: | 24 hours | | Result: | Significantly decreased the expression of Bcl2 and significantly increased the expression of Bax and cleaved-caspase3, with no effect on total caspase-3. |
|
体内研究
(In Vivo) | Flurbiprofen (0.3-4.8 mg/kg; p.o.; 4-5 dosages) has acute anti-inflammatory in adrenalectomized rats[2].
Flurbiprofen (10 mg/kg; i.p.; daily; for 6 days) attenuates high-fat diet-induced obesity in mice[3].
| Animal Model: | Rat[2] | | Dosage: | 0.3 mg/kg, 0.6 mg/kg, 1.2 mg/kg, 2.4 mg/kg, 4.8 mg/kg | | Administration: | Oral administration, 4-5 dosages | | Result: | Inhibited the acute inflammation. |
|
| Clinical Trial | |
| 分子量 | |
| 性状 | |
| Formula | |
| CAS 号 | |
| 中文名称 | 氟比洛芬；氟联苯丙酸；苯氟布洛芬；氟苯布洛芬；氟布洛芬；氟吡洛芬 |
| 运输条件 | Room temperature in continental US; may vary elsewhere. |
| 储存方式 | | Powder | -20°C | 3 years | | 4°C | 2 years | | In solvent | -80°C | 6 months | | -20°C | 1 month |
|
| 溶解性数据 | In Vitro: DMSO : ≥ 100 mg/mL(409.40 mM) *"≥" means soluble, but saturation unknown. 配制储备液 | 1 mM | 4.0940 mL | 20.4700 mL | 40.9400 mL | | 5 mM | 0.8188 mL | 4.0940 mL | 8.1880 mL | | 10 mM | 0.4094 mL | 2.0470 mL | 4.0940 mL |
*请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80℃, 6 months; -20℃, 1 month。-80℃ 储存时，请在 6 个月内使用，-20℃ 储存时，请在 1 个月内使用。 In Vivo: 请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照In Vitro方式配制澄清的储备液，再依次添加助溶剂： ——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；
以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶 1. 请依序添加每种溶剂： 10% DMSO 40%PEG300 5%Tween-80 45% saline Solubility: ≥ 2.5 mg/mL (10.23 mM); Clear solution
此方案可获得 ≥ 2.5 mg/mL (10.23 mM，饱和度未知) 的澄清溶液。 以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。 2. 请依序添加每种溶剂： 10% DMSO 90% (20%SBE-β-CDin saline) Solubility: ≥ 2.5 mg/mL (10.23 mM); Clear solution
此方案可获得 ≥ 2.5 mg/mL (10.23 mM，饱和度未知) 的澄清溶液。 以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。 3. 请依序添加每种溶剂： 10% DMSO 90%corn oil Solubility: ≥ 2.5 mg/mL (10.23 mM); Clear solution
此方案可获得 ≥ 2.5 mg/mL (10.23 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。 以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。 *以上所有助溶剂都可在本网站选购。
|
